Price Chart

Profile

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
URL https://www.neoleukin.com
Investor Relations URL http://investor.aqxpharma.com/
HQ State/Province Washington
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 29, 2024 (est.)
Last Earnings Release Nov. 14, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
URL https://www.neoleukin.com
Investor Relations URL http://investor.aqxpharma.com/
HQ State/Province Washington
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 29, 2024 (est.)
Last Earnings Release Nov. 14, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A